New Arthritis Drug Clears FDA Panel
- Share via
An advisory panel of the Food and Drug Administration recommended for approval the first of a new class of drugs designed to work as well as existing analgesics but without painful, dangerous side effects. FDA advisors in Silver Spring, Md., voted to back G. D. Searle’s Celebrex, the first of a class of drugs known as COX-2 inhibitors, for treating both osteoarthritis, the “wear and tear” form of arthritis, and rheumatoid arthritis, an autoimmune disease caused when the immune system mistakenly attacks the joints. Both are marked by swollen, painful joints.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
